Compare LFVN & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LFVN | KPTI |
|---|---|---|
| Founded | N/A | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.0M | 36.7M |
| IPO Year | 1996 | 2013 |
| Metric | LFVN | KPTI |
|---|---|---|
| Price | $6.32 | $0.88 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $7.50 | $7.25 |
| AVG Volume (30 Days) | 36.6K | ★ 1.4M |
| Earning Date | 11-03-2026 | 11-02-2026 |
| Dividend Yield | ★ 3.29% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.40 | N/A |
| Revenue | ★ $203,204,000.00 | $146,067,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.34 | $27.98 |
| P/E Ratio | $15.60 | ★ N/A |
| Revenue Growth | ★ 1.86 | 0.57 |
| 52 Week Low | $3.90 | $0.85 |
| 52 Week High | $11.71 | $10.99 |
| Indicator | LFVN | KPTI |
|---|---|---|
| Relative Strength Index (RSI) | 48.79 | 23.57 |
| Support Level | $6.26 | N/A |
| Resistance Level | $6.51 | $2.16 |
| Average True Range (ATR) | 0.21 | 0.16 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 53.71 | 0.00 |
Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product Geographically, its products are sold in the regions of in the United States, Mexico, Canada, Japan, Taiwan, Thailand, Australia, New Zealand, the United Kingdom, the Netherlands, Germany, Austria, Spain, Ireland, Belgium, and Others. The company operates in a single operating segment by selling products directly to customers through an international network of independent consultants that operate in an integrated manner.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).